Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327
  • The ASX-lister announced it had registered R327 with the Australian and New Zealand Clinical Trial Registry for a phase I/II topical burns study
  • The study is set to test 30 patients over two weeks in a bid to test the efficacy of the drug
  • In a broader context, Recce said the application represents one of the final administration stages required before the trial can commence
  • Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26

Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.

The company today announced the drug had been registered with the Australian and New Zealand Clinical Trial Registry (ANZCTR) for a phase I/II topical burns study in humans.

In a broader context, Recce said the registration represents one of the final administration stages required before the trial can commence.

The ANZCTR includes trials from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies.

The trial has been registered under 'Proof of Concept Study of RECCE 327 Topical
Antibiotic Therapy for Infected Burn Wounds in Adults' and will involve 30 patients to test the efficacy of RECCE 327.

Over the course of 14 days, 10 patients are set to receive R327 daily while the remaining 20 receive treatment three times per week.

Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26 at 3:42 pm AEST.

RCE by the numbers
More From The Market Herald
Oventus Medical (ASX:OVN) - Chairman, Sue MacLeman (centre left) - The Market Herald

" Oventus Medical (ASX:OVN) eyes $5M placement to strengthen balance sheet

Sleep apnoea specialist Oventus Medical (OVN) has received firm commitments to undertake a $5 million placement.
Telix Pharmaceuticals (ASX:TLX) - CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) commences prostate cancer clinical trial

Telix Pharmaceuticals (TLX) has been given the green light to commence a phase three clinical trial of its targeted therapy candidate TLX591 in
Bod Australia (ASX:BDA) - CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) records highest ever month of MediCabilis sales

Bod Australia (BDA) has recorded its highest-ever month of medicinal cannabis sales, filling 1789 MediCabilis prescriptions in April.
Prescient Therapeutics (PTX) -CEO & Managing Director, Steven Yatomi - The Market Herald

" Prescient Therapeutics (ASX:PTX) signs new research agreement with Peter MacCallum Cancer Centre

Prescient Therapeutics (PTX) has announced a new research program with the Peter MacCallum Cancer Centre to advance its next-generation CAR-T programs.